The latest on the coronavirus pandemic and vaccines
A Phase 3 trial of biotechnology company Novavax's Covid-19 vaccine shows it has an efficacy of 89.3%, the company announced on Thursday. But the company highlighted the vaccine's…
A Phase 3 trial of biotechnology company Novavax's Covid-19 vaccine shows it has an efficacy of 89.3%, the company announced on Thursday. But the company highlighted the vaccine's…